Skip to main content
Erschienen in: Annals of Hematology 11/2017

19.08.2017 | Original Article

Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia

verfasst von: Yinjun Lou, Yafang Ma, Jianai Sun, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Jie Jin

Erschienen in: Annals of Hematology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Early death is the main obstacle for the cure of patients with acute promyelocytic leukemia (APL). We have analyzed risk factors of early death from 526 consecutive newly diagnosed APL patients between 2004 and 2016. The overall incidence of early death was 7.2% (38/526). The peak hazard of early death occurred in the first 0–3 days. Multivariate logistic analysis demonstrated white blood cell (WBC) counts [odds ratio (OR) = 1.039; 95% confidence interval (CI): 1.024–1.055; P < 0.001], age (OR = 1.061; 95% CI: 1.025–1.099; P = 0.001) and platelet counts (OR = 0.971; 95% CI: 0.944–0.999; P = 0.038) were independent risk factors for early death. Furthermore, receiver-operator characteristic (ROC) curve analyses revealed a simple WBC/platelet ratio was significantly more accurate in predicting early death [areas under the ROC curve (AUC) = 0.842, 95% CI: 0.807–0.872) than WBC counts (AUC = 0.793; 95% CI: 0.756–0.827) or Sanz score (AUC = 0.746; 95% CI: 0.706–0.783). We stratified APL patients into four risk subgroups: low risk (WBC ≤ 10 × 109/L, platelet >40 × 109/L), intermediate risk (WBC/platelet <0.2 and age ≤ 60, not in low risk), high risk (WBC/platelet ≥0.2 or age > 60, not in low and ultra-high risk) and ultra-high risk (WBC > 50 × 109/L), the early death rates were 0, 0.6, 12.8, and 41.2%, respectively. In conclusion, we proposed a modified Sanz risk model as a useful predictor of early death risk in patients with APL.
Literatur
1.
Zurück zum Zitat de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66(4):675–684CrossRefPubMed de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66(4):675–684CrossRefPubMed
2.
Zurück zum Zitat Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121. doi:10.1056/NEJMoa1300874 CrossRefPubMed Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121. doi:10.​1056/​NEJMoa1300874 CrossRefPubMed
3.
Zurück zum Zitat Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF (2015) Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology 2(9):e357–e366. doi:10.1016/s2352-3026(15)00115-5 CrossRefPubMed Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF (2015) Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology 2(9):e357–e366. doi:10.​1016/​s2352-3026(15)00115-5 CrossRefPubMed
4.
Zurück zum Zitat Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 16(13):1295–1305. doi:10.1016/s1470-2045(15)00193-x CrossRefPubMed Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 16(13):1295–1305. doi:10.​1016/​s1470-2045(15)00193-x CrossRefPubMed
5.
Zurück zum Zitat Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 106(9):3342–3347. doi:10.1073/pnas.0813280106 CrossRefPubMedPubMedCentral Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 106(9):3342–3347. doi:10.​1073/​pnas.​0813280106 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(4):504–510. doi:10.1200/JCO.2008.18.6130 CrossRef Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(4):504–510. doi:10.​1200/​JCO.​2008.​18.​6130 CrossRef
8.
Zurück zum Zitat Lou Y, Ma Y, Suo S, Ni W, Wang Y, Pan H, Tong H, Qian W, Meng H, Mai W, Huang J, Yu W, Wei J, Mao L, Jin J (2015) Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res 39(9):938–944. doi:10.1016/j.leukres.2015.05.016 CrossRefPubMed Lou Y, Ma Y, Suo S, Ni W, Wang Y, Pan H, Tong H, Qian W, Meng H, Mai W, Huang J, Yu W, Wei J, Mao L, Jin J (2015) Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res 39(9):938–944. doi:10.​1016/​j.​leukres.​2015.​05.​016 CrossRefPubMed
9.
Zurück zum Zitat Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Ades L (2009) Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(16):2668–2676. doi:10.1200/JCO.2008.18.4119 CrossRef Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Ades L (2009) Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(16):2668–2676. doi:10.​1200/​JCO.​2008.​18.​4119 CrossRef
10.
Zurück zum Zitat Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Cortes J, Ravandi F (2017) Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129 (10):1275–1283. doi:10.1182/blood-2016-09-736686 Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Cortes J, Ravandi F (2017) Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129 (10):1275–1283. doi:10.​1182/​blood-2016-09-736686
11.
Zurück zum Zitat Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(6):605–612. doi:10.1200/JCO.2016.67.1982 CrossRef Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(6):605–612. doi:10.​1200/​JCO.​2016.​67.​1982 CrossRef
12.
Zurück zum Zitat Abedin S, Altman JK (2016) Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2016(1):10–15. doi:10.1182/asheducation-2016.1.10 Abedin S, Altman JK (2016) Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2016(1):10–15. doi:10.​1182/​asheducation-2016.​1.​10
13.
Zurück zum Zitat Tallman M, Lo-Coco F, Kwaan H, Sanz M, Gore S (2011) Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. Clinical advances in hematology & oncology : H&O 9(2):1–16 Tallman M, Lo-Coco F, Kwaan H, Sanz M, Gore S (2011) Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. Clinical advances in hematology & oncology : H&O 9(2):1–16
14.
Zurück zum Zitat Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Rangert Derolf Å, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia 25(7):1128–1134. doi:10.1038/leu.2011.78 CrossRefPubMed Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Rangert Derolf Å, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia 25(7):1128–1134. doi:10.​1038/​leu.​2011.​78 CrossRefPubMed
16.
Zurück zum Zitat Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Mahmud S, Meloche C, Sabloff M, Sharif I, Storring J, Turner D, Seftel MD (2014) Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 166(5):660–666. doi:10.1111/bjh.12931 CrossRefPubMed Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Mahmud S, Meloche C, Sabloff M, Sharif I, Storring J, Turner D, Seftel MD (2014) Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 166(5):660–666. doi:10.​1111/​bjh.​12931 CrossRefPubMed
17.
Zurück zum Zitat Rahme R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Ades L (2014) Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia 28(12):2422–2424. doi:10.1038/leu.2014.240 CrossRefPubMed Rahme R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Ades L (2014) Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia 28(12):2422–2424. doi:10.​1038/​leu.​2014.​240 CrossRefPubMed
18.
Zurück zum Zitat Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, Myhr-Eriksson K, Mollgard L, Uggla B, Wahlin A, Wennstrom L, Hoglund M, Juliusson G (2017) Early death rates remain high in high-risk APL: update from the Swedish acute leukemia registry 1997-2013. Leukemia 31(6):1457–1459. doi:10.1038/leu.2017.71 Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, Myhr-Eriksson K, Mollgard L, Uggla B, Wahlin A, Wennstrom L, Hoglund M, Juliusson G (2017) Early death rates remain high in high-risk APL: update from the Swedish acute leukemia registry 1997-2013. Leukemia 31(6):1457–1459. doi:10.​1038/​leu.​2017.​71
19.
Zurück zum Zitat Jacomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, Bittencourt HN, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92(10):1431–1432. doi:10.3324/haematol.10874 CrossRefPubMed Jacomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, Bittencourt HN, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92(10):1431–1432. doi:10.​3324/​haematol.​10874 CrossRefPubMed
20.
Zurück zum Zitat Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F (2010) Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 95(5):853–854. doi:10.3324/haematol.2009.017962 CrossRefPubMed Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F (2010) Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 95(5):853–854. doi:10.​3324/​haematol.​2009.​017962 CrossRefPubMed
22.
Zurück zum Zitat Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247–1253PubMed Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247–1253PubMed
23.
Zurück zum Zitat Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31(33):4215–4221. doi:10.1200/JCO.2013.48.8312 CrossRef Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31(33):4215–4221. doi:10.​1200/​JCO.​2013.​48.​8312 CrossRef
24.
Zurück zum Zitat Shen ZX (2011) Chinese guidelines for the diagnosis and treatment of acute promyelocytic leukemia. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 32(12):885–886PubMed Shen ZX (2011) Chinese guidelines for the diagnosis and treatment of acute promyelocytic leukemia. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 32(12):885–886PubMed
25.
Zurück zum Zitat Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J (2013) High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res 37(1):37–42. doi:10.1016/j.leukres.2012.09.004 CrossRefPubMed Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J (2013) High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res 37(1):37–42. doi:10.​1016/​j.​leukres.​2012.​09.​004 CrossRefPubMed
26.
Zurück zum Zitat Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J (2014) Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematol Oncol 32(1):40–46. doi:10.1002/hon.2076 CrossRefPubMed Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J (2014) Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematol Oncol 32(1):40–46. doi:10.​1002/​hon.​2076 CrossRefPubMed
27.
Zurück zum Zitat Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101(15):5328–5335. doi:10.1073/pnas.0400053101 CrossRefPubMedPubMedCentral Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101(15):5328–5335. doi:10.​1073/​pnas.​0400053101 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111(7):3395–3402. doi:10.1182/blood-2007-07-100669 CrossRefPubMed de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111(7):3395–3402. doi:10.​1182/​blood-2007-07-100669 CrossRefPubMed
30.
Zurück zum Zitat Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(33):4417–4423. doi:10.1200/JCO.2011.35.7525 CrossRef Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(33):4417–4423. doi:10.​1200/​JCO.​2011.​35.​7525 CrossRef
32.
Zurück zum Zitat Rego EM, Kim HT, Ruiz-Arguelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutierrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillon LA, Gomez-Almaguer D, Kwaan HC, Garces-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Lowenberg B, Sanz MA (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the international consortium on APL. Blood 121(11):1935–1943. doi:10.1182/blood-2012-08-449918 CrossRefPubMed Rego EM, Kim HT, Ruiz-Arguelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutierrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillon LA, Gomez-Almaguer D, Kwaan HC, Garces-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Lowenberg B, Sanz MA (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the international consortium on APL. Blood 121(11):1935–1943. doi:10.​1182/​blood-2012-08-449918 CrossRefPubMed
Metadaten
Titel
Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia
verfasst von
Yinjun Lou
Yafang Ma
Jianai Sun
Sansan Suo
Hongyan Tong
Wenbin Qian
Wenyuan Mai
Haitao Meng
Jie Jin
Publikationsdatum
19.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3096-5

Weitere Artikel der Ausgabe 11/2017

Annals of Hematology 11/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.